SAJE Pharma Home

GSNOR Inhibition has Therapeutic Activity in Many Diseases

SAJE Pharma, LLC is a biopharmaceutical company focused on developing new therapeutic agents that provide significant benefits over available therapies for rare and common diseases with unmet medical needs.

SAJE Pharma started operations in 2011 after obtaining an exclusive license to innovative S-nitrosoglutathione reductase inhibition (GSNORi) technology that targets the last and controlling step in the nitrosylation signal transduction pathway that regulates many therapeutically important cellular responses.

With management and advisors experienced in nitrosylation research and development, SAJE Pharma is positioned to be a leader in the development of new therapies for multiple diseases, including: inflammatory and autoimmune diseases such as rheumatoid and osteoarthritis, Crohn’s disease, ulcerative colitis, psoriasis, and other autoimmune diseases; metabolic diseases such as diabetes and non-alcoholic steatohepatatitis (NASH); cardiovascular diseases such as acute heart attack, heart failure, and recovery after an interventional cardiology procedure; respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and asthma; and neurodegenerative diseases such as multiple sclerosis, Alzheimer’s, and Parkinson’s. To date, GSNORis have been therapeutically effective in 21 animal models of disease including examples in all of the categories listed above. Since inflammation, oxidant damage, fibrosis, and mitochondrial dysfunction drive many chronic and acute diseases, all of which are controlled by GSNOR inhibition, it is predictable that many other diseases can be treated with this therapy.

The SAJE team has over 125 years of in depth drug research and development expertise from discovery chemistry to regulatory filings. This broad range of expertise enables SAJE to move development projects forward that provide the greatest potential for clinical benefit and success. It is the goal of SAJE Pharma to manage our programs through the early phases of clinical development thereby building company value with novel therapies.

lab worker